$9.87
+0.15 (+1.54%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where HLN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
56 interventional · 1 observational · 37 with posted results
Held by 19 tracked-famous managers (Dodge & Cox, HARRIS ASSOCIATES L P, Point72 Asset Management, L.P., First Eagle Investment Management, LLC, JANE STREET GROUP, LLC, +14 more) · FINRA short interest 1.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity SufferersNCT07337109observationalChange From Baseline in Total DHEQ Score Over 12 Months | — | Recruiting | — | Dentin Hypersensitivity | 375 | Feb 2027 | ≤ 192 d | 2026-04-28 |
| Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity ReliefNCT07300540Change From Baseline in DHEQ Total Score at Week 24Open-label · Other | Not applicable | Active, not recruiting | Other: Calcium sodium phosphosilicate (CSPS) Toothpaste | Dentin Sensitivity | 500 | Nov 2026 | ≤ 102 d | 2026-07-21 |
| A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-AdhesiveNCT07496164Area Over Baseline (AOB) in Bite Force Over 13 Hours (AOB0-13) to Compare the Maximum Incisal Bite Force Until Maxillary Denture Dislodgement (Experimental Denture Adhesives Versus [Vs] No Denture Adhesive)Randomized · Single-masked · Device feasibility | Not applicable | Recruiting | Device: Experimental Denture Adhesive 1, Experimental Denture Adhesive 2, Experimental Denture Adhesive 3, Poligrip Power Hold + Seal | Denture Retention | 60 | Nov 2026 | ≤ 102 d | 2026-04-09 |
| A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival HealthNCT07704905Change from Baseline in Overall Modified Gingival Index (MGI) at Week 8Randomized · Single-masked · Treatment | Not applicable | Recruiting | Drug: Test Dentifrice, Reference Dentifrice (Colgate Cavity Protection Dentifrice) | Dental Plaque, Gingivitis | 110 | Oct 2026 | ≤ 72 d | 2026-08-12 |
| A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 YearsNCT07632274Area Under the Plasma Concentration Versus (Vs.) Time Curve Calculated from Time 0 to the Last Measurable Sampling Time Point (AUC0-t) for Ibuprofen and AcetaminophenOpen-label · Other | Phase 1 | Recruiting | Drug: Test Product | Pain | 12 | Sep 2026 | ≤ 41 d | 2026-06-30 |
| Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel DentifriceNCT07215767Change from Baseline in Schiff sensitivity score at Week 8 (Test Dentifrice Versus [Vs] Reference Dentifrices 1, 2 and 3)Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate Dentifrice, Vehicle Dentifrice | Dentin Hypersensitivity | 688 | Aug 2026 | ≤ 11 d | 2026-06-16 |
| A Clinical Study to Evaluate the Effectiveness of an Experimental Toothpaste in Improving Gum Health and Reducing Plaque AccumulationNCT07255040Number of Bleeding Sites (Overall) at Week 24Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Test Dentifrice, Parodontax Complete Protection, Colgate Cavity Protection | Dental Plaque, Gingivitis | 284 | 2026-07-30actual | — | 2026-08-05 |
| A Study to Assess the Effectiveness of a Marketed Denture Adhesive in Real-World SettingNCT07273149Mean Score of the Food Occlusion Question Assessed Using the Numerical Rating Scale (NRS)Open-label · Other | Not applicable | Completed | Device: Poligrip Power Max Hold + Seal | Denture Retention | 375 | 2026-05-21actual | — | 2026-06-02 |
| A Clinical Study to Evaluate the Effectiveness of an Test Toothpaste for the Relief of Dentin Hypersensitivity in a Chinese PopulationNCT07352956Change From Baseline in Schiff Sensitivity Score at Day 56Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Test toothpaste, Sodium fluoride toothpaste | Dentin Sensitivity | 177 | 2026-04-06actual | — | 2026-04-14 |
| A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental ToothpastesNCT07297732Mean VITA Shade Score at Baseline, Weeks 1, 2, 4 and 8Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Test Toothpaste 1, Test Toothpaste 2, Reference Toothpaste | Dentin Hypersensitivity | 254 | 2026-03-19actual | — | 2026-03-31 |
| A Study to Evaluate the Effect of a Test (Sodium Bicarbonate) Toothpaste on the Oral MicrobiomeNCT07273539Change From Baseline in Bacterial Composition at Week 12 by Treatment GroupsRandomized · Single-masked · Basic science | Not applicable | Completed | Drug: Sodium Bicarbonate Toothpaste, Sodium Fluoride Toothpaste | Gingivitis | 74 | 2026-02-27actual | — | 2026-03-11 |
| A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed ConditionsNCT07345130Maximum Observed Post-dose Concentration (Cmax) Under Fasted Conditions (Test Versus (vs) Reference Product)Randomized · Open-label · Other | Phase 1 | Completed | Drug: Advil Tablet (Mini) (Test Product), Advil Tablet (Reference Product) | Bioequivalence, Bioavailability | 50 | 2026-02-03actual | — | 2026-03-13 |
| A Clinical Study Investigating the Efficacy of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival HealthNCT07169188Mean Bleeding Index (BI) at Week 12Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Test Fluoride Toothpaste, Colgate Cavity Protection Toothpaste | Dental Plaque, Gingivitis | 154 | 2025-12-23actual | — | 2026-01-21 |
| A Clinical Study to Assess an Experimental Dentifrice in an Experimental Model of Early Stage CariesNCT06949072Percent Surface Microhardness Recovery (%SMHr) After 2 Weeks in situ (Experimental Dentifrice Versus [Vs] Negative Control Dentifrice)Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Test Dentifrice, Reference Dentifrice, Negative Control Dentifrice | Dental Caries | 47 | 2025-09-11actual | — | 2025-09-24 |
| A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea)NCT07140341Change from Baseline in Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, And Associated Nausea) Symptoms Using VAS Scoring After 15 Minutes of Taking ENO LimeOpen-label · Treatment | Phase 3 | Completed | Drug: ENO Lime | Indigestion Acid, Indigestion, Nausea | 40 | 2025-09-06actual | — | 2025-09-17 |
| A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque AccumulationNCT06933368Number of Bleeding Sites (Overall) At Week 12Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Crest Cavity Protection Toothpaste, Experimental Mouthwash | Dental Plaque, Gingivitis | 136 | 2025-08-14actual | — | 2025-09-17 |
| Clinical Study to Investigate the Ability of a Stannous Fluoride Toothpaste to Protect From Dentine HypersensitivityNCT06733285Least Square (LS) Mean Change from Baseline in Schiff Sensitivity Score at Day 15Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Sensodyne Rapid Relief, Colgate Cavity Protection | Dentin Sensitivity | 85 | 2025-05-27actual | — | 2025-06-03 |
| Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting ConditionsNCT06855576results2026-07-01Maximum Observed Concentration (Cmax) for Paracetamol ODT (Test) Versus (vs.) Paracetamol (Alvedon Film-coated Tablet) (Reference 1)Randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Paracetamol ODT, Alvedon film-coated tablet, Panadol film-coated Tablet | Fever, Pain | 54 | 2025-04-17actual | — | 2026-07-01 |
| A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult SubjectsNCT06802185Maximum Observed Post-dose Concentration (Cmax) for Ibuprofen Under Fasted Conditions (ADA Liquid Filled Capsules [Treatment A] vs. ADA Caplet [Treatment B])Randomized · Open-label · Other | Phase 1 | Completed | Drug: ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product) | Pain | 54 | 2025-04-12actual | — | 2025-04-23 |
| Quantification of Diclofenac 2.32% (Voltaren) in Rinse Water After Different Application MethodsNCT06954181results2026-06-16Concentration of Voltaren® Schmerzgel Forte; 2.32% (Diclofenac) in Water (Milligrams Per Liter [mg/L]) After WashingNon-randomized · Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Voltaren® Schmerzgel forte; 2.32% (Test Product) | Healthy Participants | 33 | 2025-04-11actual | — | 2026-06-16 |
| A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque AccumulationNCT06660069results2026-03-18Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste), CPC Mouthwash (Parodontax Active Gum Health Mouthwash), Regular Fluoride Toothpaste (Crest Cavity Protection), Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste) | Dental Plaque, Gingivitis | 199 | 2025-03-11actual | — | 2026-03-18 |
| A Study Evaluating Quality of Life Parameters Following Use of Emergen-CNCT06654089results2026-03-10Adjusted Mean Change From Baseline in Multidimensional Fatigue Inventory (MFI) General Fatigue Domain Score at Week 12Randomized · Double-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Dietary supplement: Emergen-C Core Super Orange Powder, Placebo | Dietary Supplements | 299 | 2025-02-24actual | — | 2026-04-07 |
| A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With RobitussinNCT06716645results2026-02-20Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total ScoreRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Robitussin Maximum Strength Cough and Chest Congestion DM, Robitussin Maximum Strength Cough and Chest Congestion DM, Robitussin Maximum Strength Nighttime Cough DM | Common Cold, Cough | 244 | 2025-02-14actual | — | 2026-02-20 |
| A Clinical Study Investigating the Effect of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival HealthNCT06602466results2026-01-22Adjusted Mean Bleeding Index (BI) at Week 4Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Test toothpaste, Colgate Cavity Protection Toothpaste | Dental Plaque, Gingivitis | 175 | 2024-12-13actual | — | 2026-01-22 |
| A Clinical Study Assessing the Effects of a Marketed Dentifrice on Tooth Sensitivity While Undergoing Tooth BleachingNCT06608368results2025-12-15Visual Analogue Scale (VAS) Scores of the Tooth Sensitivity Questionnaire Collected Through the StudyRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Test Dentifrice (Sensodyne Repair and Protect Original Mint), Positive Control Dentifrice (Sensodyne Fresh Mint), Reference Dentifrice (Crest Cavity Protection Regular) | Dentin Sensitivity | 90 | 2024-11-15actual | — | 2025-12-15 |
| A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis PainNCT06379893results2026-01-20Change From Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Voltaren Gel | Pain | 196 | 2024-10-29actual | — | 2026-01-20 |
| A Clinical Study to Evaluate the Anti-Sensitivity Effect of a Calcium Sodium Phosphosilicate Toothpaste in a Population of Dentin Hypersensitivity SufferersNCT06378008results2025-09-08Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Day 56Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: CSPS toothpaste, Regular fluoride toothpaste (Crest Cavity Protection) | Dentin Sensitivity | 217 | 2024-09-04actual | — | 2025-09-08 |
| A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth BleachingNCT06150573results2025-07-24Adjusted Mean VITA Shade Score at 24 Weeks After Tooth BleachingRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Test Dentifrice, Reference Dentifrice (Aquafresh Cavity Protection) | Dentin Sensitivity, Oral Hygiene | 160 | 2024-07-18actual | — | 2025-07-24 |
| A Clinical Study to Evaluate the Anti-Sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity SufferersNCT06354270results2025-06-25Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Day 56Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Stannous fluoride toothpaste, Regular fluoride toothpaste (Crest Cavity Protection) | Dentin Sensitivity | 115 | 2024-06-23actual | — | 2025-06-25 |
| Clinical Study to Evaluate the Anti-sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity SufferersNCT06359028results2025-06-24Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Day 56Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Stannous fluoride toothpaste, Crest cavity protection toothpaste | Dentin Sensitivity | 111 | 2024-06-20actual | — | 2025-06-24 |
| A Study to Evaluate the Effect of a Stannous Fluoride Toothpaste on the Oral MicrobiomeNCT06048809results2025-07-10Alpha Diversity at Baseline (Day 1)Randomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Stannous Fluoride Toothpaste (Sensodyne Repair and Protect), Regular Fluoride Toothpaste (Colgate Cavity Protection) | Oral Health | 56 | 2024-05-30actual | — | 2025-07-10 |
| An Erosion Study to Investigate the Efficacy of an Experimental Dentifrice to Remineralize EnamelNCT06242444results2025-05-08Adjusted Mean Percent Surface Microhardness Recovery (%SMHR) at 4 Hours (Test Dentifrice Versus (vs.) Placebo Control Dentifrice)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Experimental Dentifrice, Placebo Control Dentifrice, Reference Dentifrice | Tooth Erosion | 33 | 2024-05-07actual | — | 2025-05-08 |
| A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity ManagementNCT06045026results2025-04-24Adjusted Mean Change From Baseline in DHEQ Total Score (Section 2, Question [Q]1-34) at Weeks 4, 8, 12, 16, 20 and 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Stannous fluoride | Dentin Sensitivity | 536 | 2024-04-25actual | — | 2025-04-24 |
| A Clinical Study Investigating the Effects of a Dentifrice Containing 0.454% Stannous Fluoride on Gingivitis Treatment and Plaque Reduction When Used Twice Daily for 12 WeeksNCT06143670results2025-03-21Adjusted Mean Change From Baseline in the Number of Bleeding Sites (NBS) at Week 12Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Stannous fluoride toothpaste, Sodium fluoride toothpaste | Gingivitis | 159 | 2024-03-12actual | — | 2025-03-21 |
| A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque RemovalNCT05654662results2025-01-13Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 12Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Corsodyl Original Dentifrice, Colgate Cavity Protection Dentifrice | Gingivitis, Dental Plaque | 197 | 2023-11-30actual | — | 2025-01-13 |
| A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste for the Relief of Dentine Hypersensitivity in a Chinese PopulationNCT05750745results2024-11-20Adjusted Mean Change From Baseline in Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Week 12 (Test Dentifrice Versus [vs.] Negative Control)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Sensodyne Sensitivity & Gum, Crest Cavity Protection Fresh Lime, Sensodyne Repair and Protect | Dentin Sensitivity | 416 | 2023-09-19actual | — | 2024-11-20 |
| A Bioequivalence Study of Two Ibuprofen Arginine Granules 400 mg Formulations Under Fasting and Fed Conditions in Chinese Healthy Adult SubjectsNCT05737069results2024-09-19Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted ConditionsRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Ibuprofen arginine granules 400 mg, Ibuprofen arginine granules 400 mg (Spedifen) | Pain | 84 | 2023-05-15actual | — | 2024-09-19 |
| A Bioequivalence Study of Advil PM Liqui-Gels Minis (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) Compared to the Current Marketed Advil PM Liqui-Gels (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) in Healthy Adult Subjects Under Fasted ConditionsNCT05674721results2024-08-23Maximum Observed Plasma Concentration (Cmax) for IbuprofenRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Advil PM Liqui-Gels Minis, Advil PM Liqui-Gels | Pain | 77 | 2023-03-21actual | — | 2024-08-23 |
| Otrivine: Quality of Life (QoL) Impact in a Real-World SettingNCT05556148results2024-05-17Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total ScoreOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Otrivine Congestion Relief | Common Cold | 136 | 2022-12-20actual | — | 2024-05-17 |
| Clinical Study to Investigate the Tooth Stain Removal Efficacy of Two Experimental Toothpastes Compared to a Standard Toothpaste When Used Twice Daily for 8 WeeksNCT05459558results2024-04-12Change From Baseline in Mean Total Modified Lobene Stain Index (MLSI) Score at Week 8Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: Experimental Dentifrice 1, Experimental Dentifrice 2, Reference Dentifrice | Oral Hygiene | 280 | 2022-12-04actual | — | 2024-04-12 |
| A Clinical Study to Examine the Effects of an Experimental Toothpaste Compared to a Regular Fluoride Toothpaste on Breath Odor in a Population With GingivitisNCT05524948results2024-08-26Adjusted Mean Change From Baseline (Day 0, Pre-Brushing) to Week 3 (Pre-Brushing) in Breath Organoleptic ScoresRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Experimental Dentifrice, Reference Dentifrice | Halitosis | 104 | 2022-10-27actual | — | 2024-08-26 |
| Exploratory Clinical Study to Investigate the Ability of an Experimental Combination Dentifrice to Protect Sensitive TeethNCT05243745results2024-09-20Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Baseline (Day 0)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: 3% PVM/MA + 5% KNO3 Combination, 3% PVM/MA only, 5% KNO3 Only, Regular Fluoride | Dentin Sensitivity | 120 | 2022-10-03actual | — | 2024-09-20 |
| A Clinical Study to Evaluate the Maximum Maxillary Bite Force (BF) When Using Two Novel Denture Adhesives Compared to Using No-AdhesiveNCT05173974results2024-02-16Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite ForceRandomized · Single-masked · Device feasibilityStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Device: Super Poligrip Free, Experimental Denture Adhesive 1, Experimental Denture Adhesive 2 | Denture Retention | 45 | 2022-07-12actual | — | 2024-02-16 |
| Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult ParticipantsNCT05265247results2024-02-05Maximum Observed Post Dose Concentration (Cmax)Randomized · Double-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Esomeprazole 20 mg Delayed-Release Capsules, Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR) | Gastrointestinal Diseases | 61 | 2022-06-02actual | — | 2024-02-05 |
| A Real-World Evidence Study to Evaluate Oral Health Related Quality of Life Using an Anti-Sensitivity ToothpasteNCT04964063results2024-01-22Mean Score of DHEQ Section 1 - Impact on Everyday Life (Question [Q]1-3) at Baseline (Day 0)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Potassium Nitrate + Sodium Fluoride | Dentin Sensitivity | 655 | 2022-05-13actual | — | 2024-01-22 |
| A Clinical Study to Evaluate the Efficacy of a Range of Dental/Denture Products for Improved Oral Health in Partial Denture WearersNCT04290624results2023-11-18Mean Bleeding Index (BI) at Week 12Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Other: Experimental Dentifrice: Stannous Fluoride, Mouth rinse: Sodium Fluoride · Device: COREGA Denture Foaming Cleanser | Gingivitis | 58 | 2022-02-24actual | — | 2023-11-18 |
| A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity in a Chinese PopulationNCT04950465results2023-10-23Change From Baseline in Schiff Sensitivity Score at Week 8 (Test Dentifrice Versus [vs.] Negative Control)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Sensodyne Sensitivity & Gum, Crest Cavity Protection Fresh Lime, Sensodyne Repair and Protect | Dentin Sensitivity | 271 | 2022-01-25actual | — | 2023-10-23 |
| Clinical Study to Evaluate the 80-Minute Water Resistant Sun Protection Factor (SPF) of Sunscreen ProductsNCT05124899results2024-04-26Arithmetic Mean SPF ValuesRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: CAP UnScented, CAP Herbal Mint, CAP Mountain Berry, SPF Standard Sunscreen | Sunscreening Agents | 15 | 2021-12-18actual | — | 2024-04-26 |
| Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip Balm ProductNCT05109117results2024-03-29Mean Change From Baseline in Corneometer MeasurementsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: CAP Unscented | Sunscreening Agents | 39 | 2021-12-17actual | — | 2024-03-29 |
| Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen ProductsNCT05109104results2024-04-19Arithmetic Mean SPF ValuesRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: CAP UnScented, CAP Herbal Mint, CAP Mountain Berry, SPF Standard Sunscreen | Sunscreening Agents | 13 | 2021-12-15actual | — | 2024-04-19 |
| Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip BalmNCT05082376results2024-04-19Mean Change From Baseline in Corneometry Value at Each Post-treatment TimepointRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: CLM Original | Sunscreening Agents | 38 | 2021-11-11actual | — | 2024-04-19 |
| Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen ProductsNCT05085327results2024-03-25Arithmetic Mean SPF ValuesRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: ChapStick Lip Moisturizer Original, ChapStick Lip Moisturizer Mint, ChapStick Lip Moisturizer Black Cherry, SPF Standard Sunscreen | Sunscreening Agents | 11 | 2021-11-04actual | — | 2024-03-25 |
| A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult SmokersNCT05024747results2024-03-21Maximum Observed Plasma Nicotine Concentration (Cmax) of NicoDerm CQ Dungarvan (Test) Compared to NicoDerm CQ, Alza (Reference)Randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza) | Tobacco Use Disorder | 22 | 2021-10-25actual | — | 2024-03-21 |
| A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult SubjectsNCT05022810results2024-02-20The Area Under the Plasma Concentration [AUC] Versus Time Curve Calculated From Time Zero to the Last Measurable Sampling Time Point (Tlast) (AUC [0-tlast])Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: New Paracetamol Oral Suspension (24 mg/ml), Panadol B&I Oral Suspension (24 mg/ml paracetamol) | Pain | 61 | 2021-09-08actual | — | 2024-02-20 |
| Study to Investigate the Effect of Changes in Dentinal Hypersensitivity on Oral Health ParametersNCT07768969Change From Baseline in Schiff Sensitivity ScoreSingle-masked · Treatment | Not applicable | Completed | Other: Test Toothpaste | Dentine Hypersensitivity | 75 | 2014-03-04actual | — | 2026-08-17 |
| Study to Evaluate the Effectiveness of Test Dentifrice in the Relief of Dentinal HypersensitivityNCT07317128results2026-05-13Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Week 12 (Test Dentifrice Versus [vs] Negative Control Dentifrice)Randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Test Dentifrice, Colgate Sensitive ProRelief, Colgate Triple Protection | Dentin Sensitivity | 120 | 2013-06-08actual | — | 2026-05-13 |
| A Study to Evaluate the Dentinal Hypersensitivity Efficacy of Two Experimental Mouthwash FormulationsNCT07741032Change From Baseline in Schiff Sensitivity Score at Weeks 4, 6 and 8Randomized · Single-masked · Treatment | Not applicable | Completed | Other: 3% KNO3 Mouthwash, 2% HPC Mouthwash, 0% KNO3 Mouthwash | Dentine Hypersensitivity | 118 | 2012-07-09actual | — | 2026-08-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19